

THE LANCET

Rheumatology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Cavalli G, Colafrancesco S, De Luca G, et al. Cutaneous vasculitis following COVID-19 vaccination. *Lancet Rheumatol* 2021; published online Sept 30.
[https://doi.org/10.1016/S2665-9913\(21\)00309-X](https://doi.org/10.1016/S2665-9913(21)00309-X).

Supplementary Table 1. Clinical features, lab findings, and therapies of all patients.

Sex, age (years)	Onset following vaccination	Cutaneous involvement	Visceral involvement	Lab tests: CRP, ESR	Lab tests: other *	Treatment (PDN-equivalent)
M, 57	14 days (1 st dose)	Lower and upper limbs, abdomen, trunk, head	None	CRP 27 mg/dL ESR 17 mm/h	Negative or normal	1 mg/Kg for 3 weeks, followed by tapering
M, 58	7 days (2 nd dose)	Lower limbs, abdomen, trunk	None	CRP 52 mg/L ESR 79 mm/1h	Negative or normal	1 mg/Kg for 14 days, followed by tapering
F, 53	6 days (1 st dose)	Lower and upper limbs	None	CRP 7 mg/L ESR 35 mm/1h	Negative or normal	1 mg/Kg for 14 days, followed by tapering

Figure Legend. CRP: C-reactive protein. ESR: erythrocyte sedimentation rate. * Other lab tests included: ANCA, cANCA, pANCA, rheumatoid factor, cryoglobulins, anti-nuclear antibodies, anti-DNA antibodies, C3 and C4 complement fractions, cryoglobulins, IgA, and serology for HBV and HCV. PDN: prednisone.

Supplementary Figure 1. Cutaneous vasculitis, Patient 2



Supplementary Figure 2. Skin biopsy, Patient 3. Histologic evaluation of a 5 mm punch biopsy revealed a slight lymphocytic perivascular infiltrate. Hematoxylin and eosin, original magnification 200x.

